A comparative study of optimal medical care with and without azaserine in multiple myeloma

James F. Holland; Edmund A. Gehan; Clyde O. Brindley; Marguerida M. Dederick; Albert H. Owens; Bruce I. Shnider; Robert Taylor; Emil Frei; Oleg S. Selawry; William Regelson; Thomas C. Hall

doi:10.1002/cpt19612122

A comparative study of optimal medical care with and without azaserine in multiple myeloma

James F. Holland, Edmund A. Gehan, Clyde O. Brindley, Marguerida M. Dederick, Albert H. Owens, Bruce I. Shnider, Robert Taylor, Emil Frei, Oleg S. Selawry, William Regelson, Thomas C. Hall

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

A comparative clinical study o f optimal medical care plus azaserine versus optimal medical care plus a placebo was accomplished in 20 patients with multiple myeloma. Azaserine was originally studied in myeloma because o f reported effects on a plasma cell neoplasm in mice. The controlled study was undertaken because suggestive activity in myeloma had previously been seen. The 9 azaserine-treated patients sustained more toxicity than the 11 placebo-treated patients. No important difference in tumor behavior was detectable between the azaserine- and placebo-treated groups as determined by physical examination or the several hematologic, biochemical, and roentgenologic measurements made.

Original language	English
Pages (from-to)	22-28
Number of pages	7
Journal	Clinical Pharmacology and Therapeutics
Volume	2
Issue number	1
DOIs	https://doi.org/10.1002/cpt19612122
State	Published - 1961
Externally published	Yes

Access to Document

10.1002/cpt19612122

Cite this

@article{e46188cd0b70449682f8b45efb6d70dc,

title = "A comparative study of optimal medical care with and without azaserine in multiple myeloma",

abstract = "A comparative clinical study o f optimal medical care plus azaserine versus optimal medical care plus a placebo was accomplished in 20 patients with multiple myeloma. Azaserine was originally studied in myeloma because o f reported effects on a plasma cell neoplasm in mice. The controlled study was undertaken because suggestive activity in myeloma had previously been seen. The 9 azaserine-treated patients sustained more toxicity than the 11 placebo-treated patients. No important difference in tumor behavior was detectable between the azaserine- and placebo-treated groups as determined by physical examination or the several hematologic, biochemical, and roentgenologic measurements made.",

author = "Holland, {James F.} and Gehan, {Edmund A.} and Brindley, {Clyde O.} and Dederick, {Marguerida M.} and Owens, {Albert H.} and Shnider, {Bruce I.} and Robert Taylor and Emil Frei and Selawry, {Oleg S.} and William Regelson and Hall, {Thomas C.}",

year = "1961",

doi = "10.1002/cpt19612122",

language = "English",

volume = "2",

pages = "22--28",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - A comparative study of optimal medical care with and without azaserine in multiple myeloma

AU - Holland, James F.

AU - Gehan, Edmund A.

AU - Brindley, Clyde O.

AU - Dederick, Marguerida M.

AU - Owens, Albert H.

AU - Shnider, Bruce I.

AU - Taylor, Robert

AU - Frei, Emil

AU - Selawry, Oleg S.

AU - Regelson, William

AU - Hall, Thomas C.

PY - 1961

Y1 - 1961

N2 - A comparative clinical study o f optimal medical care plus azaserine versus optimal medical care plus a placebo was accomplished in 20 patients with multiple myeloma. Azaserine was originally studied in myeloma because o f reported effects on a plasma cell neoplasm in mice. The controlled study was undertaken because suggestive activity in myeloma had previously been seen. The 9 azaserine-treated patients sustained more toxicity than the 11 placebo-treated patients. No important difference in tumor behavior was detectable between the azaserine- and placebo-treated groups as determined by physical examination or the several hematologic, biochemical, and roentgenologic measurements made.

AB - A comparative clinical study o f optimal medical care plus azaserine versus optimal medical care plus a placebo was accomplished in 20 patients with multiple myeloma. Azaserine was originally studied in myeloma because o f reported effects on a plasma cell neoplasm in mice. The controlled study was undertaken because suggestive activity in myeloma had previously been seen. The 9 azaserine-treated patients sustained more toxicity than the 11 placebo-treated patients. No important difference in tumor behavior was detectable between the azaserine- and placebo-treated groups as determined by physical examination or the several hematologic, biochemical, and roentgenologic measurements made.

UR - http://www.scopus.com/inward/record.url?scp=50849149962&partnerID=8YFLogxK

U2 - 10.1002/cpt19612122

DO - 10.1002/cpt19612122

M3 - Article

C2 - 13715278

AN - SCOPUS:50849149962

SN - 0009-9236

VL - 2

SP - 22

EP - 28

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -

A comparative study of optimal medical care with and without azaserine in multiple myeloma

Abstract

Access to Document

Fingerprint

Cite this